D. Mark Layton

1.2k total citations
34 papers, 652 citations indexed

About

D. Mark Layton is a scholar working on Physiology, Genetics and Hematology. According to data from OpenAlex, D. Mark Layton has authored 34 papers receiving a total of 652 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Physiology, 18 papers in Genetics and 16 papers in Hematology. Recurrent topics in D. Mark Layton's work include Erythrocyte Function and Pathophysiology (21 papers), Hemoglobinopathies and Related Disorders (18 papers) and Blood groups and transfusion (9 papers). D. Mark Layton is often cited by papers focused on Erythrocyte Function and Pathophysiology (21 papers), Hemoglobinopathies and Related Disorders (18 papers) and Blood groups and transfusion (9 papers). D. Mark Layton collaborates with scholars based in United Kingdom, United States and Canada. D. Mark Layton's co-authors include Rachael F. Grace, Wilma Barcellini, Barbara Wild, A. D. Stephens, M. R. A. LALLOZ, Hanny Al‐Samkari, Ranganath Parthasarathy, Kris Noel Dahl, Connie M. Westhoff and Kevin H.M. Kuo and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Blood.

In The Last Decade

D. Mark Layton

32 papers receiving 637 citations

Peers

D. Mark Layton
Ching‐Tien Peng Taiwan
Martin Sorette United States
J. Riou France
RP Hebbel United States
Sujin Kanokpongsakdi Thailand
Antonino Giambona Italy
Ronald F. Rieder United States
May‐Jean King United Kingdom
RS Schwartz United States
Ryan Philip Jajosky United States
Ching‐Tien Peng Taiwan
D. Mark Layton
Citations per year, relative to D. Mark Layton D. Mark Layton (= 1×) peers Ching‐Tien Peng

Countries citing papers authored by D. Mark Layton

Since Specialization
Citations

This map shows the geographic impact of D. Mark Layton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Mark Layton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Mark Layton more than expected).

Fields of papers citing papers by D. Mark Layton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Mark Layton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Mark Layton. The network helps show where D. Mark Layton may publish in the future.

Co-authorship network of co-authors of D. Mark Layton

This figure shows the co-authorship network connecting the top 25 collaborators of D. Mark Layton. A scholar is included among the top collaborators of D. Mark Layton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Mark Layton. D. Mark Layton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ordóñez-Mena, José M, Xuejuan Fan, Debasish Kar, et al.. (2025). Assessing the association between COVID-19 vaccination and thrombotic thrombocytopenia syndrome (ATTEST Study): Analyses of English data, 2020-2022. International Journal of Infectious Diseases. 164. 108289–108289.
2.
Layton, D. Mark & Barbara J. Bain. (2025). Acanthocytosis Contributes to the Diagnosis of the McLeod Syndrome. American Journal of Hematology. 100(10). 1851–1852. 1 indexed citations
3.
Grace, Rachael F., Eduard J. van Beers, Joan‐Lluís Vives Corrons, et al.. (2023). The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design. BMJ Open. 13(3). e063605–e063605. 3 indexed citations
4.
5.
6.
Bain, Barbara J., et al.. (2022). Voxelotor in sickle cell disease. American Journal of Hematology. 97(6). 830–832. 2 indexed citations
7.
Kuo, Kevin H.M., D. Mark Layton, Ashutosh Lal, et al.. (2021). Long-Term Efficacy and Safety of the Oral Pyruvate Kinase Activator Mitapivat in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia. Blood. 138(Supplement 1). 576–576. 4 indexed citations
8.
Al‐Samkari, Hanny, Rachael F. Grace, Oliver Andrés, et al.. (2021). Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-Term Treatment with Mitapivat. Blood. 138(Supplement 1). 924–924. 3 indexed citations
9.
Al‐Samkari, Hanny, Rachael F. Grace, Oliver Andrés, et al.. (2020). Early-Onset Osteopenia and Osteoporosis in Patients with Pyruvate Kinase Deficiency. Blood. 136(Supplement 1). 30–32. 4 indexed citations
10.
Howard, Jo, Claire Hemmaway, Paul Telfer, et al.. (2019). A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease. Blood. 133(17). 1865–1875. 84 indexed citations
11.
Grace, Rachael F., Paola Bianchi, Bertil Glader, et al.. (2019). An Ongoing Global, Longitudinal, Observational Study of Patients with Pyruvate Kinase Deficiency: The PEAK Registry. Blood. 134(Supplement_1). 2223–2223. 2 indexed citations
12.
Grace, Rachael F., D. Mark Layton, Frédéric Galactéros, et al.. (2017). Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency. Blood. 130. 2194–2194. 2 indexed citations
13.
Uttenthal, Benjamin J., D. Mark Layton, Timothy J. Vyse, & Benjamin Schreiber. (2012). The Wolf at the Door. New England Journal of Medicine. 366(23). 2216–2221. 10 indexed citations
14.
Roper, David, et al.. (2011). Splenic infarction in a patient with sickle cell trait and hereditary spherocytosis. American Journal of Hematology. 86(8). 695–696. 6 indexed citations
15.
Pavlů, Jiří, et al.. (2007). Myocardial infarction in sickle-cell disease. The Lancet. 369(9557). 246–246. 20 indexed citations
16.
Lin, Hua‐Tay, Michael P. Brady, R. K. Richards, & D. Mark Layton. (2005). Characterization of erosion and failure processes of spark plugs after field service in natural gas engines. Wear. 259(7-12). 1063–1067. 20 indexed citations
17.
Richards, R. K., D. Mark Layton, Hua‐Tay Lin, & Michael P. Brady. (2004). Characterization of Erosion Mechanisms of Natural Gas Engine Spark Plugs. 723–742.
18.
Wild, Barbara, et al.. (2001). Rapid Identification of Hemoglobin Variants by Electrospray Ionization Mass Spectrometry. Blood Cells Molecules and Diseases. 27(3). 691–704. 83 indexed citations
19.
Bain, Barbara J., R. Amos, D. Bareford, et al.. (1998). THE LABORATORY DIAGNOSIS OF HAEMOGLOBINOPATHIES. British Journal of Haematology. 101(4). 783–792. 102 indexed citations
20.
Pagliuca, Antonio, D. Mark Layton, Steven L. Allen, & G J Mufti. (1988). Hyperinfection with strongyloides after treatment for adult T cell leukaemia-lymphoma in an African immigrant.. BMJ. 297(6661). 1456–1457. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ching‐Tien Peng Breakdown of academic impact, for papers by Martin Sorette Breakdown of academic impact, for papers by J. Riou Breakdown of academic impact, for papers by RP Hebbel Breakdown of academic impact, for papers by Sujin Kanokpongsakdi Breakdown of academic impact, for papers by Antonino Giambona Breakdown of academic impact, for papers by Ronald F. Rieder Breakdown of academic impact, for papers by May‐Jean King Breakdown of academic impact, for papers by RS Schwartz Breakdown of academic impact, for papers by Ryan Philip Jajosky
Rankless by CCL
2026